In 2008, three research teams independently identified anoctamin 1 (ANO1) or transmembrane protein 16a (TMEM16A) as a CaCC, which they proposed as a potential CF therapeutic target7–9. The gene discussed is ANO1; the disease is cystic fibrosis.